Mark Warren, MD
Endocrinologist, Diabetes & Metabolism and Internal Medicine
Physicians East PA
This enduring activity will cover the treatment and management of patients who are overweight or obese and have osteoarthritis of the knee.
At the completion of this activity, participants will be able to:
- Assess evidence on the correlation between weight loss and improvements in osteoarthritis of the knee, including joint function and pain
- Evaluate clinical trial data on the efficacy and safety of current and emerging pharmacologic therapies for the management of obesity
- Incorporate guideline recommendations, patient-specific factors, and clinical trial data into treatment plans for the management of co-morbid obesity and osteoarthritis of the knee
This educational activity is intended for rheumatologists, orthopedic surgeons, endocrinologists, primary care physicians, and other healthcare professionals who diagnose, treat, and manage overweight and obese patients with osteoarthritis of the knee.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.00 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses who diagnose, treat, and manage overweight and obese patients with osteoarthritis of the knee.
Credits: 1.0 ANCC Contact Hour
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.00 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Dr. Warren discloses that he is on the speakers’ bureau for Novo Nordisk, Sanofi, Amgen, Eli Lilly and AstraZeneca. He is a consultant for Novo Nordisk and Eli Lilly. Dr. Warren has also completed contracted research for Eli Lilly, Gan & Lee, Novo Nordisk, and Takeda.
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Outcomes Coordinator for Med Learning Group has nothing to disclose.
Diana Tommasi, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, Dr. Warren may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete and submit the evaluation form to Med Learning Group.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at email@example.com.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.
RELEASE DATE: November 20, 2020
EXPIRATION DATE: November 20, 2021
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.